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1. Introduction 
Cardiac amyloidosis is a rare and complex pathology resulting in infiltrative restrictive 
cardiomyopathy and there are only very few clinical pathways through which the 
diseased amyloidotic heart may be a subject of cardiosurgical intervention. Cardiac 
surgery may rarely be warranted in very selected cases, and, on the other hand, may be 
performed mistakenly in misdiagnosed patients with cardiac amyloidosis. In clinical 
terms, the accumulation of expertise is hampered by the scarcity of its occurrence, 
heterogeneity of etiological subgroups, late clinical manifestation and polymorphous 
nature of symptoms. 
The term amylon was first coined by Matthias Schleiden, German botanist, in 1838, for waxy 
starch in plants. In 1842 Karl Rokitansky described amyloidosis in connection with 
hepatosplenomegaly and Rudolf Virchow used in 1854 iodine for staining of amyloid. 
Today, more than one and half century later, we recognize amyloidosis as a heterogeneous 
infiltrative disease in which insoluble protein deposits are accumulated in various organs 
with deleterious effects on their functional integrity. Kidney, heart, blood vessels, central 
and peripheral nervous systems, liver, intestines, lungs, eyes, skin or bones may be affected 
(Cohen 1967). 
2. Classification of cardiac amyloidosis 
Cardiac amyloidosis is classified with regard to the origin of protein precursors in 6 types: 
primary (AL), secondary (reactive, AA), senile systemic, hereditary (familial), isolated atrial 
and hemodialysis-associated amyloidosis. Differentiation between these forms is based on 
immunohistochemical and genetic testing and implies the patient´s prognosis and 
therapeutic strategies. 
Primary amyloidosis (AL) is the disease of immunoglobulin light-chain proteins produced 
from plasma cells in multiple myeloma and other plasma cell dyscrasias (Waldenström 
macroglobulinemia, B-cell lymphoma, a. o.). Its incidence is rare, estimated for 8.9 per 
million population (Kyle, Linos et al. 1992), however, its clinical course is aggressive with 
poor prognosis.  The median survival without treatment is 13 months and may be 
prolonged to 17 months with melphalane and prednisone therapy (Kyle, Gertz et al. 1997). 
Predominant cardiac involvement is the cause of dim course with median life expectancy of 
4 months since clinical manifestation of congestive heart failure. Death is attributed to 
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intractable low cardiac output or fatal arrhytmia. Sudden cardiac death may be preceded by 
syncope (Chamarthi, Dubrey et al. 1997). 
Secondary amyloidosis (AA) is caused by the accumulation of amyloid A fibrils formed 
from an acute-phase reactant, serum amyloid A protein, in chronic inflammatory diseases 
like rheumatoid arthritis, familial Mediterranean fever, chronic infections, chronic lung 
diseases, tuberculosis, and inflammatory bowel disease. The heart seems to be affected less 
frequently whereas the kidney involvement leads to proteinuria and renal failure. The 
treatment of the underlying inflammatory process can reverse the disease (Gillmore, Lovat 
et al. 2001). 
Senile systemic amyloidosis is related to liver production of a wild-type transthyretin 
transport protein (TTR). Amyloid deposits can be found in the heart, aorta, brain, pancreas, 
lung, liver, kidneys, and other organs. Senile systemic amyloidosis seems to be an age 
related disease, affecting predominantly men above the age of 70, with age-increasing 
incidence. Median survival of 75 months indicates less aggressive course of the disease 
(Cohen 1967; Ng, Connors et al. 2005). 
Hereditary (familial) amyloidosis is an autosomal dominant disease in which genetically 
mutated proteins, namely TTR, form the insoluble deposits. More than 80 transthyretin 
mutation have been identified as well as mutations in other proteins (fibrinogen Aa, 
lysozyme, apolipoprotein A-I, and gelsolin) have also been reported  (Connors, Richardson 
et al. 2000). Besides cardiac involvement the other manifestations are peripheral and 
autonomic polyneuropathy with mainly gastrointestinal symptoms, renal impairment. 
Isolated atrial amyloidosis (AANF) is caused by atrial natriuretic peptide secretion in 
response to atrial dilation in valvular disease and chronic atrial fibrillation as well as in 
correlation to increasing age. Thin atrial amyloid deposits however do not affect 
significantly the cardiac performance. Cardiac amyloidosis may also develop in patients 
receiving long-term dialysis due to accumulation of beta2-microglobulin from chronic 
uremia  (Gorevic, Casey et al. 1985). Amyloid deposits may be found in myocardium, 
pericardium and valves with minimal clinical impact (Noel, Zingraff et al. 1987).   
3. Symptoms and diagnosis 
Early diagnosis of cardiac amyloidosis is not easy since its symptoms are polymorphous and 
do not clearly lead clinicians to think about a rare diagnosis. The dominant pathophysiology 
is restrictive cardiomyopathy resulting in a diastolic failure. Frequent are arrhythmias, 
conductions disorders and syncopes. Angina may be present from obstructive intraluminal 
coronary microangiopathy (Narang, Chopra et al. 1993; Whitaker, Tungekar et al. 2004; 
Neben-Wittich, Wittich et al. 2005; Tsai, Seldin et al. 2011) which, in usual absence of 
epicardial coronary stenoses, can be classified as syndrome X – (Yagishita, Tanimoto et al. 
2009). Low-voltage  QRS amplitudes on ECG (≤ 10 mV in all precordial leads or ≤ 5 mV in 
all limb leads) is a relatively constant finding but not very specific since it may be present 
also in obesity, emphysema, effusion, hypothyroidism and other clinical conditions (Shah, 
Inoue et al. 2006). Atrial fibrillation is common. 
Besides some indicative information from patient´s history (hematological disorders, 
chronic inflammatory processes, polyneuropathy) echocardiography, in current clinical 
practice, has the potential to raise suspicion on cardiac amyloidosis in a given patient. 
Echocardiography diagnosis of cardiac amyloidosis is based on combination of two 
dimensional (2D) a Doppler image. In 2D both left and right ventricular wall thickness is 
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increased. Size of the ventricles remains unchanged while the atria are dilated. Myocardium 
displays highly abnormal texture described as „granular and sparkling“ appearance due to 
acoustic mismatch between highly reflective amyloid deposits and normal myocardial tissue 
(Siqueira-Filho, Cunha et al. 1981). Pericardial effusion and signs of pulmonary 
hypertension are common. Pulsed wave Doppler parameters show diastolic left ventricular 
dysfunction, typically restrictive pattern, i.e. increased velocity of passive LV filling 
transmitral E wave and shortening of its deceleration time, shortening of isovolumic 
relaxation time and inversion of systolic and diastolic pulmonary vein velocity ratio. 
Cardiac catheterization can confirm the nonspecific pathophysiology of restrictive 
cardiomyopathy (elevation of diastolic pressure in both ventricles and right-sided pressure 
curve with a dip and plateau or square root sign). Normal coronarography despite angina 
complaints fits the diagnosis of cardiac amyloidosis. Cardiac magnetic resonance imaging 
enables to visualize in 3D and high-resolution morphologic dimensions of the heart and 
regional wall motion. Decreased tissue signal intensity along with late subendocardial tissue 
enhancement by gadolinium can be helpful in differentiating amyloid cardiomyopathy 
(Maceira, Joshi et al. 2005; Bucciarelli-Ducci, Locca et al. 2007). 
Ultimate diagnostic tool, though employed at advanced stage of diagnosis workup, is the 
biopsy specimen with positive Congo red staining for amyloid. Endomyocardial biopsy, if 
positive in four samples, gives almost 100% diagnostic sensitivity for amyloidosis. Tissue 
specimen can also be obtained from rectal submucosa or by abdominal fat aspiration (with 
sensitivity ranging between 75 – 85%, and 84 – 88%, respectively (Shah, Inoue et al. 2006). 
Diagnostic difficulties are obvious: before enough clinical findings are gathered to justify the 
use of sophisticated and invasive diagnostic tools, the pathway to correct diagnosis may be 
tedious. Incorporating the possibility of cardiac amyloidosis into clinician´s thinking and 
careful consideration of all available data and findings is mandatory for obtaining the 
proper diagnosis fast. 
4. Non-surgical treatment 
Conservative management of restrictive cardiomyopathy resulting from structural 
myocardial alteration is limited. Diuretics are used to balance the signs of congestive heart 
failure, with narrow margin against low-cardiac output. Calcium channel blockers are 
contraindicated for negative inotropic effect, as well as beta-blockers (Griffiths, Hughes et al. 
1982; Gertz, Falk et al. 1985; Gertz, Skinner et al. 1985). Administration of digoxin is risky 
because of its binding to amyloid fibrils and resulting toxic effects (Rubinow, Skinner et al. 
1981). Implantation of permanent pacemaker may be necessitated for conduction disorders, 
with potential for alleviation of symptoms (Mathew, Olson et al. 1997). 
Chemotherapy in AL amyloidosis, based on hematooncology strategy in treatment of 
multiple myeloma,  includes administration of melphalan orally (with prednisone (Skinner, 
Anderson et al. 1996)) or in dose-intensive intravenous protocol, followed by autologous 
blood stem cell transplantation (Comenzo, Vosburgh et al. 1998; Moreau, Leblond et al. 
1998).  The rationale is to reduce or abolish the supply of amyloidogenic monoclonal light 
chain protein from the plasma cell clone which may facilitate the regression of plasma 
deposits and improve the quality of life. Alternatively, thalidomide with dexamethasone, or 
bortezomib may be administered (Charaf, Iskandar et al. 2009).  In selected patients, the 
combined chemotherapy and stem cell transplantation may prolong the survival, however, 
it carries the risk of increased morbidity and mortality (Saba, Sutton et al. 1999).  
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5. Cardiac surgery in cardiac amyloidosis 
Cardiac surgery, in logical consequence of low prevalence of cardiac amyloidosis, difficult 
straightforward diagnostics and very limited scope of action due to the nature of the 
disease, has a relatively small window of experience. Majority of the authors have published 
anecdotic case reports and only data on transplanted patients accumulate the evidence from 
small cohorts. Basically, there are three clinical pathways in which a patient with cardiac 
amyloidosis may be referred for cardiac surgery: 
5.1 Amyloidosis misdiagnosed as a coronary artery or heart valve disease  
Unsuspected cardiac amyloidosis as a cause of sudden fatal circulatory collapse in the 
course other cardiological or surgical intervention has been reported rather early (Goldman 
and Legnami 1966; Lindholm and Wick 1986; Kotani, Hashimoto et al. 2000; Wang and 
Pollard 2000). Postmortem examination in these case reports usually reveals surprisingly 
advanced stage of structural damage of the myocardium by amyloid deposits. Striking 
disparity between the gross morphological alteration and paucity of both clinical signs and 
diagnostic findings underlines the obvious difficulties of proper management strategies in 
cardiac amyloidosis. 
Fatal response of the amyloidotic myocardium to the insult conveyed by anesthesia, general 
or cardiac surgery can be explained by concurrence of various pathophysiology 
mechanisms. Potential dysbalance of circulating volume in reaction to administration of 
anesthetic drugs cannot be adequately compensated in restrictive cardiomyopathy. Vicious 
circle is further potentiated by the myocardial inability to increase its contractile 
performance as well as by diffuse myocardial ischemia and susceptibility to arrhythmias. 
Standard treatment options, pharmacological support or counterpulsation, usually fail to 
resolve the circulatory shock. 
In recent era of high volume cardiac surgery, the risk of referral of cardiac amyloidosis 
misdiagnosed for coronary or valve disease for cardiac surgery operation keeps to be 
present despite current improvements in diagnostic process. Obvious difficulties in proper 
diagnosis making of cardiac amyloidosis are combined with systemic bias of routine clinical 
thinking. Patient´s symptoms that are indicative of far more prevalent diagnoses, namely 
coronary artery disease, prompt to perform coronarography. Though not typical for cardiac 
amyloidosis, stenoses of epicardial coronary arteries can either be clearly present on 
coronarography or at least stenoses of some degree may be assumed as a sufficient 
explanation of angina symptoms. Once labeled as patients with coronary artery disease a 
routine echocardiography is usually performed with focus on systolic ventricular function 
and presence of mitral regurgitation. When cardiac hypertrophy is not strikingly present 
diastolic dysfunction can be easily overlooked or not taken into account. 
Fatal outcome of coronary artery bypass grafting in misdiagnosed patients with cardiac 
amyloidosis has been reported by several authors (Massoudy, Szabo et al. 2003; Massias, 
Vyssoulis et al. 2006; Zacek, Medilek et al. 2007). In our institutional records (unpublished 
data) there were four fatal cases of undiagnosed cardiac amyloidosis indicated for coronary 
surgery (3x) or mitral and tricuspid valve repair (1x) (Fig. 1). In 3 ischemic patients, 
however, only two had debatable coronary stenoses while the third had a severe left main 
stenosis. Echocardiography was undiagnostic in all three of them. Postmortem microscopy 
revealed advanced stage of cardiac amyloidosis also with documented obliterative 
deposition of amyloid in small coronary vessels (Fig 2). The echocardiography of the patient 
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Fig. 1. Marked myocardial hypertrophy 610 g) in 75-year-old patient indicated for coronary 
artery bypass grafting for hemodynamically significant left main stem stenosis. Type of 
cardiac amyloidosis not identified (negative for AL, AA and senile amyloidosis). Besides 
presyncope in patient history no relevant data indicative of possible presence of amyloidosis 
were traced. 
indicated for mitral and tricuspid surgery displayed no clear indications of amyloid 
restrictive cardiomyopathy even on retrospective reevaluation.  
From the published data there is evident lack of constant and specific signs that could 
reroute in real world the misdiagnosis in process and avoid disastrous and unjustified 
cardiac operation. Low QRS voltage seems to be very constant but of low specificity. 
Interestingly, constant is the surgeon´s immediate tactile recognition of rubbery, stiff and 
nodular surface of myocardium. In obvious absence of diagnostic pattern that can safely 
indicate the correct diagnosis of cardiac amyloidosis the only advice is, first, meticulously 
include in consideration all the available data from patient history and examination, and, 
second, be sensitive for “small discrepancies” between the symptoms and objective findings 
(e.g., two of our patients had no clear angina but an effort dyspnea and fatigue were taken 
as an equivalent of this in presence of moderate stenoses on coronarography).  
Correct diagnosis of cardiac amyloidosis would prevent disastrous outcome of bypass 
surgery in case of insignificant involvement of epicardial coronary arteries. Contrary to this, 
coincidence of severe coronary disease coinciding with amyloid disease will necessitate 
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Fig. 2. Obstructive amyloid deposits in the wall of small intramyocardial artery 
(hematoxyllin-eosin, 400x) 
percutaneous coronary intervention even in a difficult topography, instead of a surgery. 
Severe valve disease in a known cardiac amyloidosis would most probably lead to decision 
for conservative treatment. 
5.2 Planned surgical intervention in correctly diagnosed cardiac amyloidosis 
In contradiction to the abovementioned, very few reports describe intentional 
reconstructive cardiac surgery in patients with diagnosed cardiac amyloidosis. In 1983, 
Goffin coined a term dystrophic valvular amyloidosis for isolated amyloid deposits in 
cardiac valves (Goffin 1980). Successful aortic valve replacement was described by Iqbal 
(Iqbal, Reehana et al. 2006). In two cases, severe mitral regurgitation from papillary 
muscle or chordae rupture was successfully treated by valve repair and valve replacement 
(Coisne, Corbi et al. 2003; Nishi, Mitsuno et al. 2008). Obstructive intramural coronary 
amyloidosis was the speculative explanation for ischemic papillary muscle rupture in the 
latter case (Coisne, Corbi et al. 2003). Namai replaced successfully both mitral and aortic 
valve for endocarditis in a 62-year-old patient with multiple myeloma combined with 
renal amyloidosis (Namai, Sakurai et al. 2010). Uneventful postoperative course in these 
rare cases indicates that degree and distribution of morphological derangement, and 
moreover, the resulting functional deficit may vary considerably and therefore cannot be 
easily estimated prospectively. 
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5.3 Heart transplantation as ultimate surgical option in amyloid cardiomyopathy 
Cardiac transplantation is logically the only substantial surgical treatment option for the 
heart with profound structural alteration due to the vast deposits of amyloid. From 
methodological point of view, however, principal concerns involve the operative risk of 
transplant surgery in patients with multiorgan amyloid disease, and the subsequent risk of 
recurrent amyloidosis in the transplanted graft. The shortage of donor organs is also 
difficult to ignore. 
The first reports of successful heart transplantation for cardiac amyloidosis are dated back to 
early 80-ties (Conner, Hosenpud et al. 1988; Hall and Hawkins 1994). Mc Gregor reported in 
1998 the Mayo Clinic experience (McGregor, Rodeheffer et al. 1998) of 8 patients but the 
largest cohort was published by Dubrey in 2004 (Dubrey, Burke et al. 2001; Dubrey, Burke et 
al. 2004) comprising 24 patients transplanted over the period of 18 years. In AL amyloidosis 
patients, the survival was 50%, 50%, and 20% at 1, 2, and 5 years in those without 
subsequent chemotherapy contrary to 71%, 71%, and 36% respectively in 7 AL transplanted 
patients  with additional chemotherapy. Without chemotherapy the median of amyloid 
recurrence in the graft was 11 months. Survival of the 7 non-AL amyloidosis patients was 
86%, 86%, and 64% at 1, 2, and 5 years. Overall 5-year survival of all amyloid patients was 
38% in contrast to 67% in patients undergoing heart transplantation for other indications 
(Dubrey, Burke et al. 2004). 
Regardless of the relatively small patient cohorts it can be assumed that the outcome of 
heart transplantation for AL amyloidosis is significantly worse than in general heart 
transplant population, namely due to progression of the systemic disease (Shah, Inoue et al. 
2006; Luo, Chou et al. 2010). 
In some clinical settings, heart transplantation may need to be combined with liver or 
kidney transplantation (Gillmore, Stangou et al. 2001; Schwartz, Kuiper et al. 2007; Audard, 
Matignon et al. 2009; Baumgratz, Vila et al. 2009). Liver transplantation should be 
instrumental or potentially curative in familial amyloidosis for abolishment of the aberrant 
transthyretin production. Scarcity of reported cases preclude consistent conclusion but it 
seems that precise knowledge of specific transthyretin mutation subtype may help to 
differentiate the outcome of transplantation strategy (Sharma, Perri et al. 2003). 
6. Conclusion 
In conclusion, cardiac amyloidosis is a complex pathology with poor prognosis since the 
onset of clinical manifestation even at the dawn of modern chemotherapy and stem cell 
transplantation. Should this disease be addressed by cardiac surgery the only therapeutic 
option is heart transplantation which, however, still remains to be debatable in view of 
postoperative results, recurrent amyloid disease of the graft and donor-organ shortage. 
Intentional cardiosurgical procedure for accompanying cardiac disorders can hardly be 
advised even in selected patients. On contrary, maximal vigilance has to be maintained to 
avoid misdiagnosing cardiac surgery for other more frequent cardiac maladies which 
otherwise can lead to unnecessary operation with fatal outcome. 
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internationally cumulative and diligent efforts will provide patients undergoing cardiac surgery with meticulous
perioperative care methods.
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